Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback